Realty Income's management, led by CEO Sumit Roy, leverages private equity expertise to drive long-term growth of 5% to 6% ...

WASHINGTON (AP) — The wealth of Dr. Mehmet Oz, the celebrity heart surgeon nominated by President Donald Trump to lead the ...

Researchers identify a new player in human immunity that can go rogue and turn the immune system against the body’s own ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Dr. Mehmet Oz has pledged to eliminate his conflicts of interest before he would helm the Centers for Medicare and Medicaid ...

Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including The Home Depot, Inc. (HD), Booking ...

AbbVie Inc. closed 5.34% below its 52-week high of $207.32, which the company reached on October 31st.

Deutsche Bank analyst James Shin downgraded Merck (MRK) to Hold from Buy with a price target of $105, down from $128. The firm believes the ...